Company & Sponsor Intelligence
Genzyme, a Sanofi Company
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed4
Countries1
Therapeutic footprint
multiple_sclerosisother_neurologyparkinsons
Indexed studies
NCT00548405Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
multiple_sclerosis · United StatesPHASE3
multiple_sclerosis · United StatesPHASE3
NCT00930553An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
multiple_sclerosis · United StatesPHASE3
multiple_sclerosis · United StatesPHASE3
NCT04221451A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2
other_neurology · United StatesPHASE3
other_neurology · United StatesPHASE3
NCT02201108Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
multiple_sclerosis · United StatesPHASE3
multiple_sclerosis · United StatesPHASE3
NCT00229736A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →